A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

G.R. Blumenschein, E.F. Smit, D. Planchard, D.W. Kim, J. Cadranel, T. De Pas, F. Dunphy, K. Udud, M.J. Ahn, N.H. Hanna, J.H. Kim, J. Mazieres, S.W. Kim, P. Baas, E. Rappold, S. Redhu, A. Puski, F.S. Wu, P.A. Janne

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)894-901
JournalAnnals of Oncology
Issue number5
Publication statusPublished - 2015

Cite this